Impact of Reimbursement for Biomarker Testing on Clinical Practice

Geoffrey R. Oxnard, MD; Lauren L. Ritterhouse, MD, PhD

Video Categories: PMO Interview with the Innovator Series: Volume 12 and Video Library

Drs. Geoffrey Oxnard and Lauren Ritterhouse deliberate on ways reimbursement issues are impacting clinical practice, particularly CMS’s “14-Day Rule.”

Related Videos

January 20, 2016

The Evolution of Stem Cells and Developing Therapies

Dr Wainberg and Dr Gerson talk about blocking cancer stem cell pathways and how randomized trials using therapies aimed at these pathways.

January 16, 2019

Navigating the CMS 14-Day Rule in Biomarker Testing

Drs. David Rimm and Roy Herbst review the problems with the CMS “14-Day Rule” since some of the multigene panel biomarker tests require 21 days or longer to complete.